Next Article in Journal
Danger-Associated Molecular Patterns (DAMPs): Molecular Triggers for Sterile Inflammation in the Liver
Next Article in Special Issue
The Multifaceted Roles of Autophagy in Flavivirus-Host Interactions
Previous Article in Journal
Molecular Cloning and Expression of MnGST-1 and MnGST-2 from Oriental River Prawn, Macrobrachium nipponense, in Response to Hypoxia and Reoxygenation
Previous Article in Special Issue
Cytokine-Modulated Natural Killer Cells Differentially Regulate the Activity of the Hepatitis C Virus
Open AccessReview

Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs

Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan
The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba 272-8516, Japan
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(10), 3103;
Received: 6 August 2018 / Revised: 1 October 2018 / Accepted: 3 October 2018 / Published: 10 October 2018
(This article belongs to the Special Issue Hepatitis Virus Infection and Molecular Research 2018)
Cirrhosis is a form of liver fibrosis resulting from chronic hepatitis and caused by various liver diseases, including viral hepatitis, alcoholic liver damage, nonalcoholic steatohepatitis, and autoimmune liver disease. Cirrhosis leads to various complications, resulting in poor prognoses; therefore, it is important to develop novel antifibrotic therapies to counter liver cirrhosis. Wnt/β-catenin signaling is associated with the development of tissue fibrosis, making it a major therapeutic target for treating liver fibrosis. In this review, we present recent insights into the correlation between Wnt/β-catenin signaling and liver fibrosis and discuss the antifibrotic effects of the cAMP-response element binding protein/β-catenin inhibitor PRI-724. View Full-Text
Keywords: liver fibrosis; Wnt; β-catenin; PRI-724 liver fibrosis; Wnt; β-catenin; PRI-724
Show Figures

Figure 1

MDPI and ACS Style

Nishikawa, K.; Osawa, Y.; Kimura, K. Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs. Int. J. Mol. Sci. 2018, 19, 3103.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop